FasDR (CD95) in many cancers, in particular Non-Hodgkin’s Lymphoma Benjamin Badger.

Slides:



Advertisements
Similar presentations
Diagnostic Immunology Topic: Immunological Tolerance Objectives: Define Immunological tolerance Define Immunological tolerance Discuss mechanism of tolerance.
Advertisements

BAFF and Autoimmune Disease
The Story of Bcl-2 Linking cell apoptosis to tumor metastasis Crystal structure of Bcl-2 complex By Yaming Wang.
Transforming Growth Factor β Receptor Type II Tina Morris
V  -J . T Cell Maturation in the Thymus Positive selection: permits the survival of only those T cells whose TCRs are capable of recognizing self-MHC.
MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.
BRCA2 Blue: Rad51; Green: BRCA2
 MicroRNAs (miRNAs) are a class of small RNA molecules, about ~21 nucleotide (nt) long.  MicroRNA are small non coding RNAs (ncRNAs) that regulate.
C22 Cancer and the Immune System Cell births ~ cell deaths; production of new cells is regulated Cells that do not respond to normal growth controls can.
Cancer immunology and immunotherapy. First an aside  Oncogenes and tumor suppressor genes.  Definitions anyone?  Oncogene –  Tumor suppressor gene.
Asthma & Exercise Physiology and Pathophysiology
CANCER. THE WORD CANCER  FEAR  DEATH  PAIN  SUFFERING  LOSS  ECONOMIC LOSS  DISFIGUREMENT  WHAT’S THE FUTURE.
Malignant Melanoma and CDKN2A
Immune Regulation and Tolerance
Molecular Medicine and Gene Therapy. Monogenetic Disorders – Single gene pathway – Multi gene pathway: But one gene only mutated Multifactorial Disorder.
Apoptosis-related Diseases  Insufficient apoptosis  Excessive apoptosis  Coexistence of insufficient and excessive apoptosis.
Group Number: 2 Britney Porter, Sandra Nguyen, Eduardo Vargas and Samender Singh Randhawa.
Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
SHIP protein identified as a B-cell tumor suppressor Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally.
T-Lymphocytes Function, Development, Subpopulations.
Specific Immune System
Jianzhong Chen, Ph.D. Institute of Immunology, ZJU.
Section 1 General Features of the Immune System
Indian Institute of Technology
Apoptosis in Cancer By: Karen Hutcherson Ryan Jenkins Angie Lam Jennie Zaborsky ISAT
Cell Suicide in Health and Disease
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Copyright © 2002 Pearson Education, Inc., publishing as Benjamin Cummings Section D: The.
Host Defense Against Tumors (Tumor Immunity)
Chapter 15.  Immunological tolerance is defined as unresponsiveness to an antigen that is induced by previous exposure to that antigen  Antigens that.
Antigen recognition in the adaptive immune system
Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,
T Cells Lacey Jeong. What is a T Cell?? Thymus cell – produced and processed by the thymus gland Lymphocyte (white blood cell) – protect body from infection.
The Problem of Cancer. What are cancer cells ? Cancerous growth involves unrestrained proliferation (malignancy) and spread (metastasis). Caused by: mutations.
Cancer and the Immune System
Immune Keytruda.
Acute Radiation Syndromes. Implications for Immunotherapy
Mechanisms of T Cell Tolerance
Modulation of Gene Expression via Disruption Of NF-kB Signaling by a
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
Autoimmune diseases Ch. 4 p (99 – 159) March 7 /2016 March
Cellular Immune response
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
Research, 2016, Vol. 4, No. 1, doi: /jfnr-4-1-6
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Chapter 9 T-cell Development
Immunological Tolerance
Tumor Immunology Ali Al Khader, MD Faculty of Medicine
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 7 Defects in apoptosis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.
BIOLOGY 12 Cancer.
Bcl-2: A Matter of Life-or-Death
(T-cell Acute Lymphoblastic Leukemia)
Mechanisms of immune escape in the tumor microenvironment.
Cancer Lecture 42 BSCI 420,421,620 Dec 11, 2002
Mechanism of CTLA-4-induced immunosuppression.
Starter Think about the feedback you got last time and make the improvements – 5 minutes.
Immunological Tolerance
Genetic Damage and Mutation
Tumor Immunology Ali Al Khader, MD Faculty of Medicine
Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.
Thomas Münzel et al. JACC 2018;71:
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours By: Anh Pham.
Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell–mediated allergic inflammation  Yong-Jun Liu, MD, PhD  Journal.
Nathalie Ganne-Carrié, Pierre Nahon  Journal of Hepatology 
Discovery of a Secreted Tumor Suppressor Provides a Promising Therapeutic Strategy for Follicular Lymphoma  Marc R. Mansour, A. Thomas Look  Cancer Cell 
Illustration of cancer cells and tumor microenvironment–deregulated miRNA target networks leading to tumor growth and progression. Illustration of cancer.
p53 loss affects several steps of the metastatic process.
 Cyclooxygenase (COX) independent chemopreventive mechanisms of non-steroidal anti-inflammatory drugs (NSAIDs). *Genes with a T cell factor 4 responsive.
Presentation transcript:

FasDR (CD95) in many cancers, in particular Non-Hodgkin’s Lymphoma Benjamin Badger

Fas activates by binding to Fas ligand, causing apoptosis—Thymic Education

Fas would logically be a tumor suppressor: if it is lost, cells cannot be instructed to undergo apoptosis as easily

(1996) Loss of Fas in mice leads to death from lymphoma

In people, Fas loss-of-function mutations are found in non-Hodgkin’s Lymphomas RT-PCR of leukemia cells shows defective splicing of Fas compared to the control (PBL). (1998)

But wait! FasR=CD95. What gives? 2010

Clue: Fas activation via mAbs causes monocytes to express proinflammatory genes. Human monocytes, grown in culture

Possible mechanisms by which death receptors could cause inflammation

Inflammation is the enemy of effective apoptosis: why would an apoptosis receptor also lead to inflammation?

Is Fas an oncogene or tumor suppressor in humans? “FAS is not significantly focally amplified across the entire dataset of 3131 tumors…(or) any of the 14 individual subtypes” but “FAS is significantly focally deleted across the entire dataset of 3131 tumors…(and) in 2 of 14 independent subtypes”

So Fas appears to be a tumor suppressor after all in humans. But “FASLG is significantly focally amplified across the entire dataset of 3131 tumors”. (Tumorscape) Why?? One reason may be so that cancer cells can activate Fas more easily (the oncogene hypothesis), but the reason could also be…

FasL is expressed by cancer cells to kill lymphocytes The Return of Thymic Eduction

References Abusamra et al. Blood Cells, Molecules and Diseases 35 (2005) Bronbaek et al. (1998) Somatic Fas Mutations in Non-Hodgkin’s Lymphoma: Association With Extranodal Disease and Autoimmunity. Blood 92: Chen et al, CD95 promotes tumour growth. Nature 465: with corrigendum (475:254, 2011). Cullen SP, Martin SJ. Fas and TRAIL ‘death receptors’ as initiators of inflammation: Implications for cancer. Semin Cell Dev Biol (2015) Douglas R. Green & Thomas A. Ferguson The role of fas ligand in immune privilege Nature Reviews Molecular Cell Biology 2, Park et al, Fas (CD95) Induces Proinflammatory Cytokine Responses by Human Monocytes and Monocyte-Derived Macrophages. J Immunology 170: Peng et al. (1996). A tumor-suppressor Function for Fas (CD95) Revealed in T Cell- deficient Mice. Journal of Experimental Medicine 184: Tumorscape (2011). The Broad Institute, data retrieved 3/15/15. Published form: Beroukhim, et al. The landscape of somatic copy-number alteration across human cancers. Nature Feb 18;463(7283):